CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells
Akito Nakamura, Takahito Hara(Takeda (Japan)), Yuichi Kakoi(Takeda (Japan)), Mihoko Kunitomo(Takeda (Japan)), Akito Hata(Takeda (United States)), Shunsuke Ebara(Takeda (Japan)), Saomi Murai(Takeda (Japan)), Daisuke Nakata(Takeda (Japan))
Cited by 49
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy
|Cell stem cell|2018|163
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116